AtaiBeckley (ATAI) Income towards Parent Company (2020 - 2026)
AtaiBeckley (ATAI) posted Income towards Parent Company of -$61.1 million for Q3 2025, down 120.04% sequentially from -$27.8 million in Q2 2025, and down 129.03% YoY from $210.3 million in Q3 2024.
Analysis
AtaiBeckley (ATAI) Income towards Parent Company (2020 - 2026) Analysis & Trends
AtaiBeckley's Income towards Parent Company history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 12.61% year-over-year to -$29.8 million; the TTM figure through Mar 2026 stood at -$56.3 million (changed N/A YoY), while the FY2025 annual figure was -$659.9 million, down 344.64% from the prior year.
- Income towards Parent Company eased to -$61.1 million in Q3 2025 per ATAI's latest filing, from -$27.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$26.5 million in Q1 2025, with the low at -$29.8 million in Q1 2026.
- A 5-year average of -$30.4 million and a median of -$31.8 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2021 and 2023: Income towards Parent Company plunged 842.61% in 2021, then soared 231.22% in 2023.
- Over 5 years, Income towards Parent Company stood at -$49.3 million in 2021, then increased by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then plunged by 107.97% to -$39.0 million in 2024, then plunged by 56.62% to -$61.1 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$61.1 million, -$27.8 million, and -$26.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | AtaiBeckley | 1.60 Bn | 1.60 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.58 Mn |
| Mar 31, 2026 | -29.98 Mn |
| Sep 30, 2025 | -61.10 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Mar 31, 2025 | -26.51 Mn |
| Dec 31, 2024 | -38.63 Mn |
| Sep 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -57.18 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -18.74 Mn |
| Sep 30, 2023 | 43.61 Mn |
| Jun 30, 2023 | -31.86 Mn |
| Mar 31, 2023 | -33.36 Mn |
| Dec 31, 2022 | -45.32 Mn |
| Sep 30, 2022 | -33.27 Mn |
| Jun 30, 2022 | -30.86 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -52.14 Mn |